Symptomatic treatment of migraine with zolmitriptan: Experience with 82 patients;Tratamiento sintomático de la migraña con zolmitriptán: Experiencia con 82 pacientes

Neurologia

Volumn 21, Issue 4, 2006, Pages 188-191

  Pascual, Julio ^a   Navarro, A ^b   Caminero, A B ^c   Jurado, C ^d   Diaz Insa, S ^e   Huerta, M ^f  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL DE VILADECANS   (Spain)

Author keywords

Intranasal zolmitript n; Migraine; Oral triptans; Subcutaneous sumatriptan

Indexed keywords

ZOLMITRIPTAN;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; NASAL PRURITUS; PALLIATIVE THERAPY; PATIENT SATISFACTION; TASTE AVERSION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLIDINONES; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 33745147595     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pascual J. Migraña. Barcelona: Masson, 2001.
2. Grupo de Estudio de Cefaleas de la Sociedad Española de Neurologia. Actitud diagnóstica y terapéutica. Madrid: Ediciones Ergon, 2004.
3. Pascual J, Leira R, Láinez JM, Alberca R, Titus F, Morales F et al. Estudio español de calidad de vida en la migraña (II). Patrón de consumo de fármacos y eficacia subjetiva. Neurología 1999;14:204-9.
4. Ceballos MA, Sánchez R, Cano A, López-Gil A. Start 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin Ther 2003;25:2053-69.
5. Wilkinson M, Pfaffenrath V, Schoenen J, Diener HC, Steiner TJ. Migraine and cluster headache their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995;15:337-57.
6. Pascual J. Experiencia con sumatriptán subcutáneo en el tratamiento sintomático de la migrana. Neurología 1994;9:282-6.
7. Yates R, Nairn K, Dixon R, Kemp JV, Dane AL. Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers. J Clin Pharmacol 2002;42:1244-50.
8. Ahonen K, Hamalainen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in the treatment of migraine attacks in children: a randomized trial. Neurology 2004;62:883-7.
9. Rapoport A. The sumatriptan nasal spray: a review of clinical trials. Cephalalgia 2001;21(Suppl. 1):13-5.
10. Syrett N, Abu-Shakra S, Yates R. Zolmitriptan nasal spray: advances in migraine treatment. Neurology 2003;61 (Suppl. 4):27-30.
11. Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003;17:653-67.
12. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: randomised, double-blind, placebo-controlled study. CNS Drugs 2005;19:125-36.
13. Gawel M, Aschoff J, May A, Charlesworth BR, REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine: results from phase 1 of the REALIZE Study. Headache 2005;45:7-16.
14. Yates R, Nairn K, Dixon R, Seaber E. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. Clin Pharmacol 2002;42:1237-43.
15. Wall A, Kagedal M, Bergström M, Jacobsson E, Nilsson D, Gunnar A, et al. Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study. Drugs in R&D 2005;6:139-47.
16. Dowson AJ, Charlesworth BR, Green J, Farkkila M, Diener HC, Hansen SB, et al. Zolmitriptan nasal spray exhibits good longterm safety and tolerability in migraine: results of the INDEX trial. Headache 2005;45:17-24.
17. Dowson AJ, Charlesworth BR, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 2003;17:839-51.
18. Pascual J, Navarro A, Caminero AB, Jurado C. Experiencia con la formulacion nasal de zolmitriptan en la cefalea en racimos. Neurologia 2006;21:131-4.